NCT05691010招募中1 期
A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 28
- 试验地点
- 7
- 主要终点
- Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer
研究概览
简要总结
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have newly diagnosed endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma.
- •Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and/or sampling). Para-aortic lymph node surgical assessment is optional.
- •Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging).
- •Patients must consent to testing with MSK-IMPACT part A and are encouraged to consent to both parts A and C.
- •Age ≥ 18 years.
- •Patients must have an Karnofsky Performance Status (KPS) ≥ 70 (or ECOG 0 or 1).
- •Neurologic function: Neuropathy (sensory and motor) grade ≤
- •No residual gross disease after surgery.
- •No prior radiation therapy or chemotherapy for treatment of endometrial cancer.
- •No active infection requiring antibiotics, except for uncomplicated urinary tract infection.
- •Patients must have adequate organ function, defined by the following laboratory results prior to first study treatment:
- •Absolute neutrophil count (ANC) ≥ 1500/mcL
- •Platelet count ≥ 100,000/mcL
- •AST/ALT ≤ 3X upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled.
- •Creatinine ≤ 1.5X ULN
- •Entry into study is limited to no more than 12 weeks from the date of surgery.
- •Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Patients of childbearing age will by definition have undergone hysterectomy and bilateral oophorectomy prior to study enrollment.
- •Participants must agree not to breastfeed during the study or for 150 days after the last dose of study treatment.
排除标准
- •Patients whose endometrial cancers harbor known pathogenic POLE mutations
- •Patients whose endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6 and/or MSI-H
- •Active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. This includes but is not limited to: uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, and superior vena cava syndrome.
- •Patients unfit for pelvic radiation therapy due to the following:
- •Has had radiation therapy encompassing >20% of the bone marrow within 2 weeks, or any radiation therapy within 1 week prior to day 1 of protocol therapy
- •Patients with a history of pelvic radiation.
- •Patients with a history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula.
- •Any hematological abnormality or disorder that would be a contraindication to radiation per the treating physician.
研究组 & 干预措施
Participants with Endometrial Cancer
Experimental
Participants have stage III endometrial cancer
干预措施: Intensity-modulated radiation therapy (Radiation)
Participants with Endometrial Cancer
Experimental
Participants have stage III endometrial cancer
干预措施: Paclitaxel (Drug)
Participants with Endometrial Cancer
Experimental
Participants have stage III endometrial cancer
干预措施: Carboplatin (Drug)
结局指标
主要结局
Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer
时间窗: up to 3 years
Feasibility of study treatment is defined as defined as the number of participants who complete all 6 planned cycles of carboplatin and paclitaxel with no delays in chemotherapy cycles greater than 21 days.
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
终止
1 期
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabCarcinoma, Non-Small Cell LungLung CancerNCT04748419University of Nebraska6
Unknown
1 期
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate CancerProstate CancerNCT01505075Sunnybrook Health Sciences Centre30
已完成
1 期
Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate CancerProstate CancerNCT01146340Sunnybrook Health Sciences Centre30
已完成
1 期
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersNon Small Cell Lung Cancer (NSCLC)MetastaticBreast CancerPancreatic CancerMelanomaNCT02639026Abramson Cancer Center at Penn Medicine53
Unknown
不适用
Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck CancerComplications RadiotherapyNCT03194061Barretos Cancer Hospital20